About A public-private partnership that supports the discovery of new medicines through open access research. Mission and Philosophy Partners Governance Collaborators Laboratories Key Achievements Strategic Alliances and Communications FAQs Sitemap Science TARGET ENABLING PACKAGES (TEPs) TISSUE PLATFORM PROTEIN STRUCTURES PUBLICATIONS CHEMICAL PROBES Epigenetics Probes Collection Human Kinase Chemical Probe Program Probes against other protein classes RECOMBINANT ANTIBODIES Structure-guided Drug Discovery Coalition (SDDC) CREATE ChemNET Research Program Trainees Open Access Learning Faculty & Industry Participants Structural & Chemical Biology Bootcamp Events Structural Biology Programme Structural Parasitology Rare Diseases Genome Integrity Growth Factor Signalling Integral Membrane Proteins Metabolic Enzymes Phosphorylation-Dependent Signalling Protein Kinases Ubiquitin Biology Chemical Biology Antibodies Protein Families Protein Methyltransferases Histone Deacetylases Histone Acetyltransferases Demethylases Bromodomains Methyl Lysine Readers Probe Development Screening Platforms Epigenetic Cell Assays Fragment Based Screening Informatics Medicinal Chemistry CHROMOHUB Phylogenetic Trees Histone Tails Epigenetics Pocketome Technological Science Biotechnology Biophysics Screening Platforms Research Informatics Protein Crystallography Medicinal Chemistry Reagents & Resources Reagents Chemical Probes Antibodies SGC Vectors SGC Plasmids SGC Constructs Resources Structure Gallery Protein Production Protocols CHROMOHUB Phylogenetic Trees Histone Tails Fragment Screening Crystal Forms Technologies High Throughput Protein Crystallisation Lex Bubbling System Frapid People Global SGC Director Aled Edwards Paul Van Damme Arij Al-Chawaf Wen Hwa Lee Amy Donner Academic Collaborators Industrial/ SME collaborators Non-Scientists Toronto Cheryl Arrowsmith Dalia Barsyte-Lovejoy Peter J. Brown Raymond Hui Jinrong Min Takis Prinos Matthieu Schapira Yufeng Tong Masoud Vedadi Oxford Chas Bountra Paul Brennan Alex N. Bullock Nicola Burgess-Brown Liz Carpenter Katharina Duerr Aude Echalier-Glazer Gillian Farnie Oleg Fedorov Panagis Filippakopoulos Opher Gileadi Kilian Huber Brian Marsden Fiona McCann Udo Oppermann Frank Von Delft Wyatt Yue UNICAMP Jon Elkins Paulo Arruda Katlin B. Massirer Mario H. Bengtson UNC Tim Willson Bill Zuercher Carrow Wells Alison Axtman David Drewry Karolinska Michael Sundström Susanne Gräslund Louise Berg Per-Johan Jakobsson Frankfurt Stefan Knapp Susanne Müller-Knapp News & Outreach News & Events SGC News Symposia & Workshops Blog Press Releases Public Events Public Engagement General Public Schools Media Patient Groups Governments TOronto Ubiquitin Club And Network (TOUCAN) Careers Tweets by thesgconline
A public-private partnership that supports the discovery of new medicines through open access research.
MS049 A chemical probe for PRMT4 and PRMT6This probe is available from Sigma, Cayman and Tocris. group newOverviewThe SGC in collaboration with the Icahn School of Medicine at Mount Sinai has developed MS049, a chemical probe for PRMT4 and PRMT6. MS049 is a potent and selective inhibitor of PRMT4,6 and is active in cells. Data relating to the discovery of this probe is being prepared for publication and its structure will be released on or before Dec 30, 2015. In the meantime, in order to facilitate research by the community we are making this compound available through this website. References Discovery of a Potent, Selective and Cell-active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6, Shen Y, Szewczyk MM, Eram MS, Smil D, Kaniskan HÜ, de Freitas RF, Senisterra G, Li F, Schapira M, Brown PJ, Arrowsmith CH, Barsyte-Lovejoy D, Liu J,Vedadi M, Jin J., J Med Chem. 2016 Sep 1.
